Brainstorm Cell Therapeutics Faces Delisting Concerns
Ticker: BCLI · Form: 8-K · Filed: Jul 17, 2025 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
Brainstorm Cell Therapeutics might get delisted - stock could tank.
AI Summary
Brainstorm Cell Therapeutics Inc. filed an 8-K on July 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates potential issues with meeting Nasdaq's continued listing requirements, which could lead to the transfer or delisting of its securities. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing signals potential delisting from a major exchange, which could significantly impact the company's stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to trade on a major exchange, posing a significant risk to its operations and stock value.
Key Players & Entities
- BRAINSTORM CELL THERAPEUTICS INC. (company) — Registrant
- July 16, 2025 (date) — Earliest event reported
- July 17, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 001-36641 (identifier) — SEC File Number
FAQ
What specific listing rule or standard has Brainstorm Cell Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that has not been met, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the potential consequence of failing to meet listing standards?
The consequence is a potential transfer of listing or delisting of the company's securities from the exchange.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on July 16, 2025.
What is the company's state of incorporation and fiscal year end?
The company is incorporated in Delaware and its fiscal year ends on December 31.
Has the company previously changed its name?
Yes, the company has had previous names including GOLDEN HAND RESOURCES INC and WIZBANG TECHNOLOGIES INC.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 17, 2025 regarding BRAINSTORM CELL THERAPEUTICS INC. (BCLI).